(R)-(+)-Etomoxir sodium salt
如果您对该产品感兴趣的话,可以
产品名称:
(R)-(+)-Etomoxir sodium salt
产品型号:
GOY-Y1938
产品展商:
谷研
产品文档:
无相关文档
发布时间:2023-04-25
简单介绍
(R)-(+)-Etomoxir sodium salt≥ 12mg/mL in DMSO
(R)-(+)-Etomoxir sodium salt
的详细介绍
|
性能参数
|
|
产品名称
|
(R)-(+)-Etomoxir sodium salt
|
|
规格
|
10mM (in 1mL DMSO) 10mg 50mg 500mg 1g
|
|
货号
|
GOY-Y1938
|
|
含量
|
>99.00%
|
|
CAS
|
828934-41-4
|
|
别名
|
N/A
|
|
|
|
化学名
|
sodium (R)-2-(6-(4-chlorophenoxy)hexyl)oxirane-2-carboxylate
|
分子式
|
C15H18ClNaO4
|
|
分子量
|
分子 320.74
|
溶解度
|
≥ 12mg/mL in DMSO
|
|
储存条件
|
Store at -20°C
|
General tips
|
|
|
用途
|
仅供科研
|
价格
|
电询
|
|
|
|
详细内容
|
Etomoxir sodium salt ((R)-(+)-Etomoxir sodium salt) is an irreversible inhibitor of carnitine palmitoyltransferase 1a (CPT-1a), inhibits fatty acid oxidation (FAO) through CPT-1a and inhibits palmitate β-oxidation in human, rat and guinea pig.
References:
[1]. Agius L, et al. Differences between human, rat and guinea pig hepatocyte cultures. A comparative study of their rates of beta-oxidation and esterification of palmitate and their sensitivity to R-etomoxir. Biochem Pharmacol. 1991 Oct 9;42(9):1711-5.
[2]. O'Connor RS, et al. The CPT1a inhibitor, etomoxir induces severe oxidative stress at commonly used concentrations. Sci Rep. 2018 Apr 19;8(1):6289.
|
公司正在销售的产品：
|
2,5-二氯噻吩-3-磺酰胺 97% 褪黑素 98%
3,5-二甲基苯并噻吩 97% 柚皮素 分析标准品，≥98%
2,4-二溴苯胺 98% 新绿原酸 99%
2，4-二巯基嘧啶 98% 三七皂甙 R1 分析标准品,≥98% (HPLC)
2,6-二甲基苯硫酚 98% 齐墩果酸 分析标准品，>98%
二苯并噻吩 99% 齐墩果酸 97%
|
TP04635185mg 10mg 50mg 100mg>98.00%Cas No. 1558021-37-6C20H18ClN3O6
UNC063810mM (in 1mL DMSO) 5mg 10mg 50mg>98.00%Cas No. 1255580-76-7C30H47N5O2
UNC 064610mM (in 1mL DMSO) 5mg 10mg 50mg>98.00%Cas No. 1320288-17-2C36H59N7O2
UNC 063110mM (in 1mL DMSO) 5mg 25mg 100mg>98.00%Cas No. 1320288-19-4C37H61N7O2
UMB-321mg 5mg 10mg 25mg>98.00%Cas No. 1635437-39-6C21H23N5O
VX-680 (MK-0457,Tozasertib)10mM (in 1mL DMSO) 50mg 100mg 250mg>98.00%Cas No. 639089-54-6C23H28N8OS
Vadadustat5mg 10mg 50mg 100mg>98.00%Cas No. 1000025-07-9C14H11ClN2O4
|